I added a PPMS trial of Ocrelizumab to the phase 3 list, based on this clinicaltrials.gov listing.

On the one hand, this is GREAT news! Any time a new substance enters phase 3 it’s a major step in the right direction. Just as importantly, it is being tested for PPMS, where the need is greatest.

On the other hand, this drug has a bit of a black cloud over it as there was a treatment-related death in the most recent phase 2 MS trial and it was discontinued as an experimental treatment for RA earlier this year due to side-effect concerns.

It’s never straight forward when it comes to treating this disease, is it?


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: